About Oncolix

Dedicated to Discovery and Development of Novel Biotherapeutics

Oncolix, Inc. (Oncolix) is a clinical-stage bio-pharmaceutical company based in Houston, Texas.

a

What we do

We are developing Prolanta™, a targeted therapeutic protein for the treatment of ovarian, breast and other cancers.

2

Strategic Alliance

Oncolix has been strategically tied up with many other renowned organizations to get supported in terms of Technological…

c

Conferences

Oncolix always had a thirst for participating in International conferences which provides a platform to improve…

 

 

 

Our Patents

US Patent Issued to Oncolix on June 17 for “Use of Prolactin Receptor Antagonists in Combination with an Agent..

more-info-btn

Scientific Publications

Since 1990 The founding Scientists of Oncolix has released many publications on endocrinology,..

more-info-btn

News & Events

ONCOLIX, INC., announced today that it has completed a Series round of financing, led by PoC Capital,…

more-info-btn


Our Science

Human Prolactin and Cancer

Human prolactin is a single-chain polypeptide of 199 amino acids with a molecular weight of approximately 23,000 Daltons.

Human Prolactin and Chemo

The antagonism of prolactin by Prolanta™ may increase the effectiveness of these chemotherapies.

Prolanta™ Structure

Prolanta™ (referenced in the scientific literature as G129R) is a prolactin receptor antagonist with a single amino acid mutation.

Ovarian Cancer and Prolanta™

Ovarian cancer is the fourth leading cause of cancer-related death in women in the US and the leading cause of

Breast Cancer and Prolanta™

Approximately 90% of breast and ovarian cancers express the prolactin receptor and these tumors are stimulated by prolactin.

Other Cancers

In addition to ovarian and breast cancers, human prolactin is also associated with many other cancers.

PROLANTA™ STRUCTURE

Prolanta™ (referenced in the scientific literature as G129R) is a prolactin receptor antagonist with a single amino acid mutation.
Human prolactin binds with its cell surface receptor (the prolactin receptor) through dimerization (or binding two receptors simultaneously), activating various pathways that

more-info-btn
Image2
Style switcher RESET
Color scheme